Atalanta Therapeutics: Raises $110M in Series A Funding

Atalanta Therapeutics, a Boston, MA-based biotechnology company pioneering new treatment options for neurodegenerative diseases, raised $110m in Series A funding
The financing was provided exclusively by F-Prime Capital
Additionally, Atalanta announced strategic collaborations with Biogen (Nasdaq: BIIB) and Genentech, a member of the Roche Group
As part of the strategic collaboration with Biogen, Atalanta will develop RNAi therapeutics for multiple targets
The company will be eligible to receive development and milestone payments on these programs as well as royalty payments on any resulting products
The strategic collaboration with Genentech involves the development of RNAi therapeutics for multiple CNS targets for neurodegenerative diseases

January 11, 2021